Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.
about
3,4-Dihydroxyphenylethanol alleviates early brain injury by modulating oxidative stress and Akt and nuclear factor-κB pathways in a rat model of subarachnoid hemorrhageBesifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness.Pediatric ocular nanomedicines: Challenges and opportunities.
P2860
Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of azithro ...... lent bacterial conjunctivitis.
@ast
Efficacy and safety of azithro ...... lent bacterial conjunctivitis.
@en
type
label
Efficacy and safety of azithro ...... lent bacterial conjunctivitis.
@ast
Efficacy and safety of azithro ...... lent bacterial conjunctivitis.
@en
prefLabel
Efficacy and safety of azithro ...... lent bacterial conjunctivitis.
@ast
Efficacy and safety of azithro ...... lent bacterial conjunctivitis.
@en
P2093
P2860
P1476
Efficacy and safety of azithro ...... lent bacterial conjunctivitis.
@en
P2093
AZI Study Group
Beata Kocyla-Karczmarewicz
Claude Speeg-Schatz
Dahbia Hartani
Didier Renault
Dominique Bremond-Gignac
Frédéric Chiambaretta
Hachemi Nezzar
Joaquim Murta
Laurent Delval
P2860
P304
P356
10.1136/BJOPHTHALMOL-2013-303888
P407
P577
2014-02-13T00:00:00Z